Total amount of the 2nd unsecured ordinary bond (private placement) issued and paid in is 100,000,000 yen. Maturity date is September 3, 2029, interest rate 0%, late surcharge 20%. Issuer is EVO FUND, with related transactions involving new share subscription rights issued to a third party.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceuticals Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4582-20260903-01.pdf","jir_short_summary":"Total amount of the 2nd unsecured ordinary bond (private placement) issued and paid in is 100,000,000 yen. Maturity date is September 3, 2029, interest rate 0%, late surcharge 20%. Issuer is EVO FUND, with related transactions involving new share subscription rights issued to a third party.","jir_summary":"### Overview\nThis bond was issued as the 2nd unsecured ordinary bond (private placement), with a total amount of 100,000,000 yen, and units of 2,500,000 yen each. Payment date is September 3, 2026, maturity date is September 3, 2029. Interest rate is 0%, late payment penalty is 20% per year. Issuer is EVO FUND, including related transactions involving third-party allocated warrants.\n\n### Future measures\/conditions\nRepayment method is a lump-sum at maturity. There may be a call option under certain conditions, and there are detailed provisions for adjustments if warrants are exercised and related payments occur.","jir_financial_highlights":"Total bonds: 100,000,000 yen (Unknown)\nMaturity date: September 3, 2029 (Unknown)\nInterest rate: annual rate 0% (Unknown)\nLate payment penalty: annual interest rate 20% (Unknown)","jir_category":"","jir_hashtags":"#SymBioPharmaceuticals, #UnsecuredBond, #PrivatePlacementPaymentCompleted","jir_key_figures":"Total bonds: 100,000,000 yen\nMaturity date: September 3, 2029\nInterest rate: annual rate 0%","jir_meta_title":"\u3010SymBio Pharmaceuticals\u30112nd Unsecured Bond (Private Placement) Payment Completion Notice\uff5c2026-09","jir_meta_description":"SymBio Pharmaceuticals announces the payment completion for the 2nd unsecured bond (private placement) totaling 100 million yen. Summary of terms: maturity date 2029\/09\/03, 0% interest, late payment penalty 20%.","jir_og_title":"\u3010SymBio Pharmaceuticals\u30112nd Unsecured Bond (Private Placement) Payment Completion Notice","jir_og_description":"SymBio Pharmaceuticals announces payment completion for the 2nd private placement. Summary of key terms including maturity date and interest rate.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-110368","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n